丙型肝炎直接抗病毒治疗研究进展

doi:10.3969/j.issn.1672-5069.2016.04.002

实用肝脏病杂志 ›› 2016, Vol. 19 ›› Issue (4): 390-393.doi: 10.3969/j.issn.1672-5069.2016.04.002

丙型肝炎直接抗病毒治疗研究进展

饶慧瑛

100044北京市北京大学人民医院肝病研究所/丙型肝炎和肝病免疫治疗北京市重点实验室

收稿日期:2016-05-05 出版日期:2016-07-30 发布日期:2016-08-31
作者简介:饶慧瑛,E-mail: raohuiying@pkuph.edu.cn

Directly acting antiviral agents in hepatitis C

Rao Huiying

Institute of Liver Diseases,People’s Hospital, Beijing University,Beijing 100044

Received:2016-05-05 Online:2016-07-30 Published:2016-08-31

摘要/Abstract

关键词: 丙型肝炎, 直接抗病毒药物, 进展

Key words: Hepatitis C, Directly acting antiviral agents, Progress

饶慧瑛. 丙型肝炎直接抗病毒治疗研究进展[J]. 实用肝脏病杂志, 2016, 19(4): 390-393.

Rao Huiying. Directly acting antiviral agents in hepatitis C[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2016, 19(4): 390-393.

[1] Fontanges T. Management of treatment with direct-acting antiviral（DAA） in clinical practice. Clin Res Hepatol Gastroenterol,2011,35（Suppl 2）:S64-S68.
[2] Moradpour D,Penin F,Rice CM. Replication of hepatitis C virus. Nat Rev Microbiol,2007,5（6）:453-463.
[3] Penin F,Dubuisson J,Rey FA,et al. Structural biology of hepatitis C virus. Hepatology,2004,39（1）:5-19.
[4] Foy E,Li K,Wang C,et al. Regulation of interferon regulatory factor-3 by the hepatitis C virus serine protease. Science, 2003,300（5622）:1145-1148.
[5] Burton JR Jr,Everson GT. HCV NS5B polymerase inhibitors. Clin Liver Dis,2009,13（3）:453-465.
[6] European Association for Study of Liver. EASL recommendations on treatment of hepatitis C 2015. J Hepatol,2015,63（1）:199-236.
[7] Rao H,Wei L,Lopez-Talavera JC,et al. Distribution and clinical correlates of viral and host genotypes in Chinese patients with chronic hepatitis C virus infection. J Gastroenterol Hepatol,2014,29（3）:545-553.
[8] Wei L,Han T,Yang D,et al. Simeprevir plus peginterferon/ribavirin for HCV genotype 1-infected treatment-naive patients in China and South Korea. J Gastroenterol Hepatol,2016,31（5）:912-920.
[9] Kumada H,Suzuki Y,Ikeda K,et al. Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. Hepatology, 2014,59（6）:2083-2091.
[10] Wei L,Zhang M,Xu M,et al. A phase 3,open-label study of daclatasvir plus asunaprevir in Asian patients with chronic hepatitis C virus genotype 1b infection who are ineligible for or intolerant to interferon alfa therapies with or without ribavirin . J Gastroenterol Hepatol,2016,doi:10.1111/jgh.13379.
[11] Lawitz E,Mangia A,Wyles D,et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med,2013,368（20）:1878-1887.
[12] Mishra P,Florian J,Qi K,et al. FDA perspective on sofosbuvir therapy for patients with chronic hepatitis C virus genotype 1 infection who did not respond to treatment with pegylated interferon and ribavirin. Gastroenterology,2014,147（6）:1196-1200.
[13] Zeuzem S,Dusheiko GM,Salupere R,et al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med,2014,370（21）:1993-2001.
[14] Lawitz E,Sulkowski MS,Ghalib R,et al. Simeprevir plus sofosbuvir,with or without ribavirin,to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients:the COSMOS randomised study. Lancet,2014,384（9956）:1756-1765.

[1]	潘美民, 李文娟, 蒋芳清, 杨丽晖, 谭永卫, 何娟, 阮建文, 蔡春琳. 慢性丙型肝炎患者血清IL-17A、FGF和IL-7水平与丙型肝炎病毒感染自发清除临床意义探讨^*[J]. 实用肝脏病杂志, 2019, 22(6): 840-843.
[2]	杨才勇, 陈娜, 李奎, 江自成, 卜蓉蓉. 慢性丙型肝炎和丙型肝炎肝硬化患者外周血Treg和Th17水平变化临床意义探讨^*[J]. 实用肝脏病杂志, 2019, 22(6): 868-871.
[3]	杨东亮, 刘嘉, 吴珺, 郑昕. 肝脏免疫学研究若干进展与挑战[J]. 实用肝脏病杂志, 2019, 22(5): 609-612.
[4]	杜科业, 杨东亮, 刘嘉. 慢性乙型肝炎与调节性T细胞研究进展^*[J]. 实用肝脏病杂志, 2019, 22(5): 613-616.
[5]	邓浩辉, 李晓强, 高洪波, 陈伟烈. HIV/HCV混合感染者与HCV感染者感染HCV基因型分析*[J]. 实用肝脏病杂志, 2019, 22(5): 656-659.
[6]	刘立, 李俊义, 杜映荣, 刘春云, 李卫昆, 王辉, 李惠敏, 常丽仙, 祁燕伟. 索磷布韦/达拉他韦治疗慢性丙型肝炎患者疗效及安全性分析：一项真实世界研究[J]. 实用肝脏病杂志, 2019, 22(3): 361-364.
[7]	张婷婷（综述）, 王煊（审校）. 肝硬化患者口服葡萄糖耐量试验临床意义及研究进展[J]. 实用肝脏病杂志, 2019, 22(3): 449-452.
[8]	孙韬华,刘振胜,辛永宁. 酒精性肝病治疗研究进展[J]. 实用肝脏病杂志, 2019, 22(2): 156-159.
[9]	蒋奕,刘冰. 慢性乙型肝炎与慢性丙型肝炎患者临床和肝组织病理学特征分析[J]. 实用肝脏病杂志, 2019, 22(2): 188-191.
[10]	吴静,东保吉,吴超. 慢性丙型肝炎患者外周血滤泡辅助性T淋巴细胞表面PD-1受体表达及意义研究^*[J]. 实用肝脏病杂志, 2019, 22(2): 192-195.
[11]	吴亚平,周冰清,蒋蓓莉. 慢性丙型肝炎患者发生重度肝纤维化相关因素分析^*[J]. 实用肝脏病杂志, 2019, 22(2): 196-199.
[12]	杨珍杰,李洪涛,王剑,李霞,陈媛. 聚乙二醇化干扰素α-2a联合利巴韦林治疗代偿期丙型肝炎肝硬化患者临床疗效研究^*[J]. 实用肝脏病杂志, 2019, 22(2): 232-235.
[13]	侯春阳, 马玉梅, 李方治. Peg-IFNα-2b联合利巴韦林治疗基因1/6型慢性丙型肝炎患者临床研究^*[J]. 实用肝脏病杂志, 2019, 22(1): 53-56.
[14]	徐溪, 党引利, 吴朔. HCV感染相关干扰素L4真核表达载体的构建与表达[J]. 实用肝脏病杂志, 2018, 21(6): 833-836.
[15]	嵇小琴综述, 龚健审校. 老年CHC临床特点及抗病毒治疗策略研究进展[J]. 实用肝脏病杂志, 2018, 21(6): 995-998.

丙型肝炎直接抗病毒治疗研究进展

Directly acting antiviral agents in hepatitis C

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价